Literature DB >> 24321977

Addressing standards of care in resource-limited settings.

Liza Dawson1, Karin L Klingman, Jeanne Marrazzo.   

Abstract

: The choice between "best-known" standards of care (SOC) or "best available" standards as the control arm in a clinical trial is a fundamental dilemma in clinical research in resource-limited settings (RLS). When the health system is delivering less than an optimal level of care, using highest standard of care in a clinical trial may produce results that cannot be implemented or sustained locally. On the other hand, using interventions that are more feasible in the local setting may involve suboptimal care, and clinical outcomes may be affected. The need for improved standards in health systems in RLS, and the difficulty in securing them, has led many researchers advocate for policy changes at the national or international level to improve clinical care more systemically. SOC decisions in a clinical trial affect the level of benefit provided to study participants and the policy implications of the trial findings. SOC choices should provide high-quality care to help advance the health care system in host countries participating in the trial, but balancing the scientific and ethical objectives of SOC choices is difficult, and there is no single formula for selecting the appropriate SOC. Despite the challenges, well-designed and conducted clinical trials can and should make significant contributions to health systems in RLS.

Entities:  

Mesh:

Year:  2014        PMID: 24321977      PMCID: PMC4169284          DOI: 10.1097/QAI.0000000000000033

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  17 in total

Review 1.  Money for research participation: does in jeopardize informed consent?

Authors:  C Grady
Journal:  Am J Bioeth       Date:  2001       Impact factor: 11.229

2.  Ancillary care in public health intervention research in low-resource settings: researchers' practices and decision-making.

Authors:  Holly A Taylor; Maria W Merritt; Luke C Mullany
Journal:  J Empir Res Hum Res Ethics       Date:  2011-09       Impact factor: 1.742

3.  Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052).

Authors:  Jessica M Fogel; Lei Wang; Teresa L Parsons; San-San Ou; Estelle Piwowar-Manning; Ying Chen; Victor O Mudhune; Mina C Hosseinipour; Johnstone Kumwenda; James G Hakim; Suwat Chariyalertsak; Ravindre Panchia; Ian Sanne; Nagalingeswaran Kumarasamy; Beatriz Grinsztejn; Joseph Makhema; Jose Pilotto; Breno R Santos; Kenneth H Mayer; Marybeth McCauley; Theresa Gamble; Namandjé N Bumpus; Craig W Hendrix; Myron S Cohen; Susan H Eshleman
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

4.  Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.

Authors:  Hoosen M Coovadia; Elizabeth R Brown; Mary Glenn Fowler; Tsungai Chipato; Dhayendre Moodley; Karim Manji; Philippa Musoke; Lynda Stranix-Chibanda; Vani Chetty; Wafaie Fawzi; Clemensia Nakabiito; Lindiwe Msweli; Roderick Kisenge; Laura Guay; Anthony Mwatha; Diana J Lynn; Susan H Eshleman; Paul Richardson; Kathleen George; Philip Andrew; Lynne M Mofenson; Sheryl Zwerski; Yvonne Maldonado
Journal:  Lancet       Date:  2011-12-22       Impact factor: 79.321

5.  Antiretroviral therapies in women after single-dose nevirapine exposure.

Authors:  Shahin Lockman; Michael D Hughes; James McIntyre; Yu Zheng; Tsungai Chipato; Francesca Conradie; Fred Sawe; Aida Asmelash; Mina C Hosseinipour; Lerato Mohapi; Elizabeth Stringer; Rosie Mngqibisa; Abraham Siika; Diana Atwine; James Hakim; Douglas Shaffer; Cecilia Kanyama; Kara Wools-Kaloustian; Robert A Salata; Evelyn Hogg; Beverly Alston-Smith; Ann Walawander; Eva Purcelle-Smith; Susan Eshleman; James Rooney; Sibtain Rahim; John W Mellors; Robert T Schooley; Judith S Currier
Journal:  N Engl J Med       Date:  2010-10-14       Impact factor: 91.245

6.  Benefits to research subjects in international trials: do they reduce exploitation or increase undue inducement?

Authors:  Angela Ballantyne
Journal:  Dev World Bioeth       Date:  2008-12       Impact factor: 2.294

7.  Community perspectives on care options for HIV prevention trial participants.

Authors:  K M MacQueen; E Namey; D A Chilongozi; S P Mtweve; M Mlingo; N Morar; C Reid; A Ristow; S Sahay
Journal:  AIDS Care       Date:  2007-04

8.  Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.

Authors:  Abubaker Bedri; Berhanu Gudetta; Abdulhamid Isehak; Solomon Kumbi; Sileshi Lulseged; Yohannes Mengistu; Arvind V Bhore; Ramesh Bhosale; Venkat Varadhrajan; Nikhil Gupte; Jayagowri Sastry; Nishi Suryavanshi; Srikanth Tripathy; Francis Mmiro; Michael Mubiru; Carolyne Onyango; Adrian Taylor; Philippa Musoke; Clemensia Nakabiito; Aida Abashawl; Rahel Adamu; Gretchen Antelman; Robert C Bollinger; Patricia Bright; Mohammad A Chaudhary; Jacqueline Coberly; Laura Guay; Mary Glenn Fowler; Amita Gupta; Elham Hassen; J Brooks Jackson; Lawrence H Moulton; Uma Nayak; Saad B Omer; Lidia Propper; Malathi Ram; Vivian Rexroad; Andrea J Ruff; Anita Shankar; Sheryl Zwerski
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

9.  Examining the challenges and solutions to the implementation of trials in resource-limited settings: Limited Resource Trials.

Authors:  Christina Blanchard-Horan; Vicki Stocker; Laura Moran; Elaine Okubo Ferguson; Karin L Klingman; Deborah McMahon; Jane Hitti
Journal:  Appl Clin Trials       Date:  2012-01-01

10.  Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.

Authors:  Thomas B Campbell; Laura M Smeaton; N Kumarasamy; Timothy Flanigan; Karin L Klingman; Cynthia Firnhaber; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Umesh Lalloo; Cynthia Riviere; Jorge Sanchez; Marineide Melo; Khuanchai Supparatpinyo; Srikanth Tripathy; Ana I Martinez; Apsara Nair; Ann Walawander; Laura Moran; Yun Chen; Wendy Snowden; James F Rooney; Jonathan Uy; Robert T Schooley; Victor De Gruttola; James Gita Hakim
Journal:  PLoS Med       Date:  2012-08-14       Impact factor: 11.069

View more
  3 in total

1.  Clinical Trial Design for HIV Prevention Research: Determining Standards of Prevention.

Authors:  Liza Dawson; Sheryl Zwerski
Journal:  Bioethics       Date:  2014-09-17       Impact factor: 1.898

Review 2.  Moving targets: The challenges of studying infectious diseases among pregnant women in resource limited settings.

Authors:  Titus H Divala; Randy G Mungwira; Miriam K Laufer
Journal:  Vaccine       Date:  2015-08-25       Impact factor: 3.641

Review 3.  Indian Council of Medical Research's National Ethical Guidelines for biomedical and health research involving human participants: The way forward from 2006 to 2017.

Authors:  Sapan Kumar Behera; Saibal Das; Alphienes Stanley Xavier; Sandhiya Selvarajan; Nishanthi Anandabaskar
Journal:  Perspect Clin Res       Date:  2019 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.